A previous study on metformin—the parent compound of imeglimin—showed that it inhibits vesicular ATP release and purinergic signaling, thereby enhancing insulin signaling and improving insulin resistance in hepatocytes [13]. The gene discussed is INS; the disease is Insulin resistance.